Health

Tackling hepatitis C

October 02, 2014

Africa

October 02, 2014

Africa
Zoe Tabary

Editor

Zoe is an Editor with Amnesty International whose role entails researching and producing reports on human rights issues. Before this Zoe was an Editor with The Economist Intelligence Unit's Thought Leadership team for almost four years. In that time she managed research projects for a number of clients across the energy, healthcare and sustainability sectors. Prior to joining The Economist Intelligence Unit she worked as a journalist in France and the UK. She holds a Master of Science in Marketing and a Bachelor’s degree in Political Science from Sciences Po Paris, and is fluent in French, Spanish and German.

Contact

An Economist Intelligence Unit report, supported by Janssen

Over a year after the publication of the hepatitis C virus (HCV) continues to pose a rising threat to healthcare systems worldwide.

As many as 170m people, or 2.4% of the world’s population, are infected with HCV, according to the World Health Organisation (WHO), nearly five times the number estimated to be living with HIV. While mortality rates as a result of acute hepatitis have remained relatively constant over the past ten years, deaths from HCV complications, such as cirrhosis of the liver, have seen a much sharper upward trajectory.

There are countries in each region of the world that suffer from high rates of infection: Georgia and Romania in Europe, Brazil and Argentina in Latin America, Mongolia, Indonesia and Taiwan in Asia, Egypt and Sub-Saharan countries in Africa, and the United States in North America. As a result, a number of these countries have played a leading role in multinational efforts to combat HCV.

In our earlier report we found that the lack of sufficient knowledge and data about the disease and its prevalence, poor public awareness, the failure to follow through consistently with treatment where testing is available, and high rates of infection among marginal populations had created significant barriers to tackling HCV. In this update, we look at what progress has been made and the barriers that remain.

 Bulletin of the World Health Organisation, 2012; 90:540-550; Guidance on prevention of viral hepatitis B and C in people who inject drugs, World Health Organisation, July 2012.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week